Julie Lang, MD, discusses real-world safety data from for the KEYNOTE-522 regimen in early triple-negative breast cancer.
Julie Lang, MD
Advertisement
Julie Lang, MD, is chief of Breast Surgery at the Lerner Research Institute and co-leader of the Breast Cancer Program at Cleveland Clinic.
Articles by Julie Lang, MD
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.
Julie Lang, MD, discusses potential applications for the Parsortix® PC1 system in metastatic breast cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5